Amlodipine Besylate Tablets

Pharmacological action: Amlodipine besylate is a dihydropyridine calcium antagonist (calcium ion antagonist or slow channel blocker). The contraction of myocardial and smooth muscle depends on the entry of extracellular calcium ions into cells through specific ion channels. This product selectively inhibits the transmembrane entry of calcium ions into smooth muscle cells and myocardial cells, and has a greater effect on smooth muscle than on myocardium. Its interaction with calcium channels is determined by the progressive rate of binding and dissociation between it and receptor sites, so the pharmacological effect is gradually produced. This product is a peripheral artery dilator that acts directly on vascular smooth muscle, reduces peripheral vascular resistance, and thus lowers blood pressure. At therapeutic doses, negative inotropic effects can be observed in in vitro experiments, but not in whole animal experiments. This product does not affect plasma calcium concentrations. 15 randomized, double-blind, placebo-controlled trials

The main ingredient of this product is amlodipine.

This product is white tablets.

(1) Hypertension (used alone or in combination with other drugs). (2) Angina pectoris: especially spontaneous angina pectoris (used alone or in combination with other drugs).

The usual starting oral dose is 5 mg, once a day, and the maximum dose is no more than 10 mg, once a day. Thin people, those with weak constitutions, elderly patients, or those with impaired liver function should start taking the drug from 2.5 mg, once a day; those who take other antihypertensive drugs in combination should also start taking the drug from this dose. The dosage is adjusted according to individual needs, and the adjustment period should be no less than 7-14 days so that the doctor can fully evaluate the patient's response to the dose. However, under the premise of clinical guarantee, the adjustment speed can be accelerated. The recommended dose for the treatment of angina pectoris is 5-10 mg, and the elderly patients or those with impaired liver function need to reduce the dose.

This product is well tolerated within the dose range of 10 mg/day, and most adverse reactions are mild to moderate. Only 1.5% of patients discontinued this product due to adverse reactions, which was not significantly different from placebo (about 1%). The most common adverse reactions are headache and edema. Dose-related adverse reactions with an incidence of 1% are as follows: edema, dizziness, hot flashes, and palpitations. Adverse reactions that are not clearly related to dose, but have an incidence of more than 1.0% are as follows: headache, fatigue, nausea, abdominal pain, and drowsiness. Among the above adverse reactions, edema, hot flashes, palpitations, and drowsiness occur more frequently in women than in men. The incidence of the following adverse events is ?1% but 0.1%, and the causal relationship with the drug is unclear: General: allergic reactions, weakness, back pain, hot flashes

Allergic to dihydropyridine calcium antagonists.

Precautions for children: The safety and effectiveness for children have not been determined. Precautions for pregnancy and lactation: There is a lack of research data on the use of this drug in pregnant women, but according to the results of animal tests, this product can only be used in pregnant women when it is absolutely necessary. It is not yet known whether this product can be secreted through breast milk. Lactating women who take this drug should stop breastfeeding. Precautions for the elderly: Clinical studies have not confirmed that the elderly react to this drug differently from young people, but considering that the elderly often have decreased liver, kidney and heart function, and are accompanied by other diseases and corresponding drug treatments, the lower limit of the dosage range is generally used for initial medication. The clearance rate of this product is reduced in the elderly, and the drug-time curve (AUC) increases by about 40%-60%, so a lower initial dose is also required.

⑴Cimetidine, grapefruit juice, acidogens: The pharmacokinetics of this product are not changed when used together. ⑵Atorvastatin, digoxin, ethanol: This product does not affect their pharmacokinetics. ⑶Sildenafil: A single dose of sildenafil (Viagra?) in patients with primary hypertension has no effect on the pharmacokinetics of this product. The two drugs produce an independent antihypertensive effect when used together. ⑷Warfarin: This product does not change the prothrombin action time of warfarin. ⑸Digoxin, phenytoin and warfarin: The combination with this product has no effect on the plasma protein binding rate. ⑹Anesthetics: Inhaled hydrocarbons combined with this product can cause hypotension. ⑺Non-steroidal anti-inflammatory drugs: Especially indomethacin can weaken the antihypertensive effect of this product. ⑻?-Blockers: Combined with this product, it is well tolerated, but it can cause excessive hypotension,

Keep in a light-proof and sealed place

5 mg

24 months.